PUBLICATIONS

Anthony Faber’s Selected Bibliography 

• Targeting SUMOylation promotes cBAF complex stabilization and disruption of the SS18::SSX transcriptome in synovial sarcoma. Floros KV, Fairchild CK Jr, Li J, Zhang K, Roberts JL, Kurupi R, Paudel D, Xing Y, Hu B, Kraskauskiene V, Hosseini N, Shen S, Inge MM, Smith-Fry K, Li L, Sotiriou A, Dalton KM, Jose A, Abdelfadiel EI, Hill RD, Slaughter JM, Shende M, Lorenz MR, Tanaka N, Kajino T, Nelson ML, Hinojosa MR, Kehinde VA, Belvin BR, Sugiokto FG, Lai Z, Dimopoulos AC, Boikos SA, Stamatouli AM, Lewis JP, Manjili MH, Ebi H, Valerie K, Li R, Poklepovic A, Koblinski JE, Siggers T, Banito A, Dozmorov MG, Jones KB, Radhakrishnan SK, Faber AC. Nat Commun. 2025 Nov 5;16(1):9761. doi: 10.1038/s41467-025-64665-8.PMID: 41193430
• A Critical Appraisal of the Utility of Targeting Therapy-Induced Senescence for Cancer Treatment. Saleh T, Greenberg EF, Faber AC, Harada H, Gewirtz DA.Cancer Res. 2025 May 15;85(10):1755-1768. doi: 10.1158/0008-5472.CAN-24-2219.PMID: 40036150
• The Innate Immune System and the TRAIL-Bcl-XL Axis Mediate a Sex Bias in Lung Cancer and Confer a Therapeutic Vulnerability in Females. May L, Hu B, Jerajani P, Jagdeesh A, Alhawiti O, Cai L, Semenova N, Guo C, Isbell M, Deng X, Faber AC, Pillappa R, Bandyopadhyay D, Wang XY, Neuwelt A, Koblinski J, Bos PD, Li H, Martin R, Landry JW. Cancer Res. 2024 Dec 16;84(24):4140-4155. doi: 10.1158/0008-5472.CAN-24-0585.PMID: 39312191
• Genomic screening reveals ubiquitin-like modifier activating enzyme 1 as a potent and druggable target in c-MYC-high triple negative breast cancer models. Jacob S, Turner TH, Cai J, Floros KV, Yu AK, Coon CM, Khatri R, Alzubi MA, Jakubik CT, Bouck YM, Puchalapalli M, Shende M, Dozmorov MG, Boikos SA, Hu B, Harrell JC, Benes CH, Koblinski JE, Costa C, Faber AC. PNAS Nexus. 2022 Oct 11;1(5):pgac232. doi: 10.1093/pnasnexus/pgac232. eCollection 2022 Nov.PMID: 36712364
• Pharmacologic Inhibition of SHP2 Blocks Both PI3K and MEK Signaling in Low-epiregulin HNSCC via GAB1. Kurupi R, Floros KV, Jacob S, Chawla AT, Cai J, Hu B, Puchalapalli M, Coon CM, Khatri R, Crowther GS, Egan RK, Murchie E, Greninger P, Dalton KM, Ghotra MS, Boikos SA, Koblinski JE, Harada H, Sun Y, Morgan IM, Basu D, Dozmorov MG, Benes CH, Faber AC. Cancer Res Commun. 2022 Sep;2(9):1061-1074. doi: 10.1158/2767-9764.crc-21-0137. Epub 2022 Sep 26.PMID: 36506869
• High-risk neuroblastoma with NF1 loss of function is targetable using SHP2 inhibition. Cai J, Jacob S, Kurupi R, Dalton KM, Coon C, Greninger P, Egan RK, Stein GT, Murchie E, McClanaghan J, Adachi Y, Hirade K, Dozmorov M, Glod J, Boikos SA, Ebi H, Hao H, Caponigro G, Benes CH, Faber AC. Cell Rep. 2022 Jul 26;40(4):111095. doi: 10.1016/j.celrep.2022.111095.PMID: 35905710
• MYCN upregulates the transsulfuration pathway to suppress the ferroptotic vulnerability in MYCN-amplified neuroblastoma. Floros KV, Chawla AT, Johnson-Berro MO, Khatri R, Stamatouli AM, Boikos SA, Dozmorov MG, Cowart LA, Faber AC. Cell Stress. 2022 Jan 17;6(2):21-29. doi: 10.15698/cst2022.02.264. eCollection 2022 Feb.PMID: 35174317
• Pharmaceutical Interference of the EWS-FLI1-driven Transcriptome By Cotargeting H3K27ac and RNA Polymerase Activity in Ewing Sarcoma. Heisey DAR, Jacob S, Lochmann TL, Kurupi R, Ghotra MS, Calbert ML, Shende M, Maves YK, Koblinski JE, Dozmorov MG, Boikos SA, Benes CH, Faber AC. Mol Cancer Ther. 2021 Oct;20(10):1868-1879. doi: 10.1158/1535-7163.MCT-20-0489. Epub 2021 Jul 26.PMID: 34315769
• Venetoclax-based Rational Combinations are Effective in Models of MYCN-amplified Neuroblastoma. Dalton KM, Krytska K, Lochmann TL, Sano R, Casey C, D’Aulerio A, Khan QA, Crowther GS, Coon C, Cai J, Jacob S, Kurupi R, Hu B, Dozmorov M, Greninger P, Souers AJ, Benes CH, Mossé YP, Faber AC. Mol Cancer Ther. 2021 Aug;20(8):1400-1411. doi: 10.1158/1535-7163.MCT-20-0710. Epub 2021 Jun 4.PMID: 34088831
• Catastrophic ATP loss underlies a metabolic combination therapy tailored for MYCN-amplified neuroblastoma. Dalton KM, Lochmann TL, Floros KV, Calbert ML, Kurupi R, Stein GT, McClanaghan J, Murchie E, Egan RK, Greninger P, Dozmorov M, Ramamoorthy S, Puchalapalli M, Hu B, Shock L, Koblinski J, Glod J, Boikos SA, Benes CH, Faber AC. Proc Natl Acad Sci U S A. 2021 Mar 30;118(13):e2009620118. doi: 10.1073/pnas.2009620118.PMID: 33762304
• Targeting transcription of MCL-1 sensitizes HER2-amplified breast cancers to HER2 inhibitors. Floros KV, Jacob S, Kurupi R, Fairchild CK, Hu B, Puchalapalli M, E Koblinski J, Dozmorov MG, Boikos SA, Scaltriti M, Faber AC. Cell Death Dis. 2021 Feb 15;12(2):179. doi: 10.1038/s41419-021-03457-6.PMID: 33589591
• MYCN-Amplified Neuroblastoma Is Addicted to Iron and Vulnerable to Inhibition of the System Xc-/Glutathione Axis. Floros KV, Cai J, Jacob S, Kurupi R, Fairchild CK, Shende M, Coon CM, Powell KM, Belvin BR, Hu B, Puchalapalli M, Ramamoorthy S, Swift K, Lewis JP, Dozmorov MG, Glod J, Koblinski JE, Boikos SA, Faber AC. Cancer Res. 2021 Apr 1;81(7):1896-1908. doi: 10.1158/0008-5472.CAN-20-1641. Epub 2021 Jan 22.PMID: 33483374
• Investigating New Mechanisms of Acquired Resistance to Targeted Therapies: If You Hit Them Harder, Do They Get Up Differently? Floros KV, Hata AN, Faber AC. Cancer Res. 2020 Jan 1;80(1):25-26. doi: 10.1158/0008-5472.CAN-19-3405.PMID: 31900282
• Respecting your elders: osimertinib demonstrates preferential activity in elderly patients with T790M positive non-small cell lung cancers. Ebi H, Boikos S, Faber AC.J Thorac Dis. 2019 Sep;11(Suppl 15):S1844-S1846. doi: 10.21037/jtd.2019.08.122.PMID: 31632765
• Epithelial-to-mesenchymal transition and drug resistance: transitioning away from death. Song KA, Faber AC.J Thorac Dis. 2019 Jun;11(6):E82-E85. doi: 10.21037/jtd.2019.06.11.PMID: 31372302
• The Ewing Family of Tumors Relies on BCL-2 and BCL-X_Lto Escape PARP Inhibitor Toxicity. Heisey DAR, Lochmann TL, Floros KV, Coon CM, Powell KM, Jacob S, Calbert ML, Ghotra MS, Stein GT, Maves YK, Smith SC, Benes CH, Leverson JD, Souers AJ, Boikos SA, Faber AC. Clin Cancer Res. 2019 Mar 1;25(5):1664-1675. doi: 10.1158/1078-0432.CCR-18-0277. Epub 2018 Oct 22.PMID: 30348635
• One gene to rule them all…and in the darkness bind them. Floros KV, Faber AC.Mol Cell Oncol. 2018 Jul 11;5(4):e1465881. doi: 10.1080/23723556.2018.1465881. eCollection 2018.PMID: 30250918
• BCL-2 inhibition is a promising therapeutic strategy for small cell lung cancer. Lochmann TL, Bouck YM, Faber AC. 2018 Aug 14;5(7-8):218-219. doi: 10.18632/oncoscience.455. eCollection 2018 Jul.PMID: 30234143
• NOTCH1 Represses MCL-1 Levels in GSI-resistant T-ALL, Making them Susceptible to ABT-263. Dastur A, Choi A, Costa C, Yin X, Williams A, McClanaghan J, Greenberg M, Roderick J, Patel NU, Boisvert J, McDermott U, Garnett MJ, Almenara J, Grant S, Rizzo K, Engelman JA, Kelliher M, Faber AC, Benes CH.Clin Cancer Res. 2019 Jan 1;25(1):312-324. doi: 10.1158/1078-0432.CCR-18-0867. Epub 2018 Sep 17.PMID: 30224339
• Increased Synthesis of MCL-1 Protein Underlies Initial Survival of EGFR-Mutant Lung Cancer to EGFR Inhibitors and Provides a Novel Drug Target. Song KA, Hosono Y, Turner C, Jacob S, Lochmann TL, Murakami Y, Patel NU, Ham J, Hu B, Powell KM, Coon CM, Windle BE, Oya Y, Koblinski JE, Harada H, Leverson JD, Souers AJ, Hata AN, Boikos S, Yatabe Y, Ebi H, Faber AC.Clin Cancer Res. 2018 Nov 15;24(22):5658-5672. doi: 10.1158/1078-0432.CCR-18-0304. Epub 2018 Aug 7.PMID: 30087143
• Targeted inhibition of histone H3K27 demethylation is effective in high-risk neuroblastoma. Lochmann TL, Powell KM, Ham J, Floros KV, Heisey DAR, Kurupi RIJ, Calbert ML, Ghotra MS, Greninger P, Dozmorov M, Gowda M, Souers AJ, Reynolds CP, Benes CH, Faber AC. Sci Transl Med. 2018 May 16;10(441):eaao4680. doi: 10.1126/scitranslmed.aao4680.PMID: 29769286
• OVOL2 in metastasis prevention in NPC. Song KA, Faber AC. 2018 Mar 8;8(8):2242-2244. doi: 10.7150/thno.25181. eCollection 2018.PMID: 29721076
• Coamplification of miR-4728protects HER2-amplified breast cancers from targeted therapy. Floros KV, Lochmann TL, Hu B, Monterrubio C, Hughes MT, Wells JD, Morales CB, Ghotra MS, Costa C, Souers AJ, Boikos SA, Leverson JD, Tan M, Serra V, Koblinski JE, Arribas J, Prat A, Paré L, Miller TW, Dozmorov MG, Harada H, Windle BE, Scaltriti M, Faber AC. Proc Natl Acad Sci U S A. 2018 Mar 13;115(11):E2594-E2603. doi: 10.1073/pnas.1717820115. Epub 2018 Feb 23.PMID: 29476008
• Venetoclax Is Effective in Small-Cell Lung Cancers with High BCL-2 Expression. Lochmann TL, Floros KV, Naseri M, Powell KM, Cook W, March RJ, Stein GT, Greninger P, Maves YK, Saunders LR, Dylla SJ, Costa C, Boikos SA, Leverson JD, Souers AJ, Krystal GW, Harada H, Benes CH, Faber AC. Clin Cancer Res. 2018 Jan 15;24(2):360-369. doi: 10.1158/1078-0432.CCR-17-1606. Epub 2017 Nov 8.PMID: 29118061
• Epithelial-to-Mesenchymal Transition Antagonizes Response to Targeted Therapies in Lung Cancer by Suppressing BIM. Song KA, Niederst MJ, Lochmann TL, Hata AN, Kitai H, Ham J, Floros KV, Hicks MA, Hu H, Mulvey HE, Drier Y, Heisey DAR, Hughes MT, Patel NU, Lockerman EL, Garcia A, Gillepsie S, Archibald HL, Gomez-Caraballo M, Nulton TJ, Windle BE, Piotrowska Z, Sahingur SE, Taylor SM, Dozmorov M, Sequist LV, Bernstein B, Ebi H, Engelman JA, Faber AC.Clin Cancer Res. 2018 Jan 1;24(1):197-208. doi: 10.1158/1078-0432.CCR-17-1577. Epub 2017 Oct 19.PMID: 29051323
• Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy Combination. Ham J, Costa C, Sano R, Lochmann TL, Sennott EM, Patel NU, Dastur A, Gomez-Caraballo M, Krytska K, Hata AN, Floros KV, Hughes MT, Jakubik CT, Heisey DA, Ferrell JT, Bristol ML, March RJ, Yates C, Hicks MA, Nakajima W, Gowda M, Windle BE, Dozmorov MG, Garnett MJ, McDermott U, Harada H, Taylor SM, Morgan IM, Benes CH, Engelman JA, Mossé YP, Faber AC.Cancer Cell. 2016 Feb 8;29(2):159-72. doi: 10.1016/j.ccell.2016.01.002.PMID: 26859456
• The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics. Hata AN, Engelman JA, Faber AC.Cancer Discov. 2015 May;5(5):475-87. doi: 10.1158/2159-8290.CD-15-0011. Epub 2015 Apr 20.PMID: 25895919
• Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer. Faber AC, Farago AF, Costa C, Dastur A, Gomez-Caraballo M, Robbins R, Wagner BL, Rideout WM 3rd, Jakubik CT, Ham J, Edelman EJ, Ebi H, Yeo AT, Hata AN, Song Y, Patel NU, March RJ, Tam AT, Milano RJ, Boisvert JL, Hicks MA, Elmiligy S, Malstrom SE, Rivera MN, Harada H, Windle BE, Ramaswamy S, Benes CH, Jacks T, Engelman JA.Proc Natl Acad Sci U S A. 2015 Mar 17;112(11):E1288-96. doi: 10.1073/pnas.1411848112. Epub 2015 Mar 3.PMID: 25737542
• Measurement of PIP3 levels reveals an unexpected role for p110β in early adaptive responses to p110α-specific inhibitors in luminal breast cancer. Costa C, Ebi H, Martini M, Beausoleil SA, Faber AC, Jakubik CT, Huang A, Wang Y, Nishtala M, Hall B, Rikova K, Zhao J, Hirsch E, Benes CH, Engelman JA.Cancer Cell. 2015 Jan 12;27(1):97-108. doi: 10.1016/j.ccell.2014.11.007. Epub 2014 Dec 24.PMID: 25544637
• Failure to induce apoptosis via BCL-2 family proteins underlies lack of efficacy of combined MEK and PI3K inhibitors for KRAS-mutant lung cancers. Hata AN, Yeo A, Faber AC, Lifshits E, Chen Z, Cheng KA, Walton Z, Sarosiek KA, Letai A, Heist RS, Mino-Kenudson M, Wong KK, Engelman JA.Cancer Res. 2014 Jun 1;74(11):3146-56. doi: 10.1158/0008-5472.CAN-13-3728. Epub 2014 Mar 27.PMID: 24675361
• PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1. Ebi H, Costa C, Faber AC, Nishtala M, Kotani H, Juric D, Della Pelle P, Song Y, Yano S, Mino-Kenudson M, Benes CH, Engelman JA.Proc Natl Acad Sci U S A. 2013 Dec 24;110(52):21124-9. doi: 10.1073/pnas.1314124110. Epub 2013 Dec 10.PMID: 24327733
• mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1. Faber AC, Coffee EM, Costa C, Dastur A, Ebi H, Hata AN, Yeo AT, Edelman EJ, Song Y, Tam AT, Boisvert JL, Milano RJ, Roper J, Kodack DP, Jain RK, Corcoran RB, Rivera MN, Ramaswamy S, Hung KE, Benes CH, Engelman JA.Cancer Discov. 2014 Jan;4(1):42-52. doi: 10.1158/2159-8290.CD-13-0315. Epub 2013 Oct 25.PMID: 24163374
• TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma. Corcoran RB, Rothenberg SM, Hata AN, Faber AC, Piris A, Nazarian RM, Brown RD, Godfrey JT, Winokur D, Walsh J, Mino-Kenudson M, Maheswaran S, Settleman J, Wargo JA, Flaherty KT, Haber DA, Engelman JA.Sci Transl Med. 2013 Jul 31;5(196):196ra98. doi: 10.1126/scitranslmed.3005753.PMID: 23903755
• Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer. Coffee EM, Faber AC, Roper J, Sinnamon MJ, Goel G, Keung L, Wang WV, Vecchione L, de Vriendt V, Weinstein BJ, Bronson RT, Tejpar S, Xavier RJ, Engelman JA, Martin ES, Hung KE.Clin Cancer Res. 2013 May 15;19(10):2688-98. doi: 10.1158/1078-0432.CCR-12-2556. Epub 2013 Apr 2.PMID: 23549875
• Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. Corcoran RB, Cheng KA, Hata AN, Faber AC, Ebi H, Coffee EM, Greninger P, Brown RD, Godfrey JT, Cohoon TJ, Song Y, Lifshits E, Hung KE, Shioda T, Dias-Santagata D, Singh A, Settleman J, Benes CH, Mino-Kenudson M, Wong KK, Engelman JA.Cancer Cell. 2013 Jan 14;23(1):121-8. doi: 10.1016/j.ccr.2012.11.007. Epub 2012 Dec 13.PMID: 23245996
• Activation of PI3K signaling in Merkel cell carcinoma. Nardi V, Song Y, Santamaria-Barria JA, Cosper AK, Lam Q, Faber AC, Boland GM, Yeap BY, Bergethon K, Scialabba VL, Tsao H, Settleman J, Ryan DP, Borger DR, Bhan AK, Hoang MP, Iafrate AJ, Cusack JC, Engelman JA, Dias-Santagata D.Clin Cancer Res. 2012 Mar 1;18(5):1227-36. doi: 10.1158/1078-0432.CCR-11-2308. Epub 2012 Jan 18.PMID: 22261808
• BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors. Faber AC, Corcoran RB, Ebi H, Sequist LV, Waltman BA, Chung E, Incio J, Digumarthy SR, Pollack SF, Song Y, Muzikansky A, Lifshits E, Roberge S, Coffman EJ, Benes CH, Gómez HL, Baselga J, Arteaga CL, Rivera MN, Dias-Santagata D, Jain RK, Engelman JA.Cancer Discov. 2011 Sep;1(4):352-65. doi: 10.1158/2159-8290.CD-11-0106. Epub 2011 Jul 22.PMID: 22145099
• An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation. Schoeberl B, Faber AC, Li D, Liang MC, Crosby K, Onsum M, Burenkova O, Pace E, Walton Z, Nie L, Fulgham A, Song Y, Nielsen UB, Engelman JA, Wong KK.Cancer Res. 2010 Mar 15;70(6):2485-94. doi: 10.1158/0008-5472.CAN-09-3145. Epub 2010 Mar 9.PMID: 20215504
• Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. Faber AC, Li D, Song Y, Liang MC, Yeap BY, Bronson RT, Lifshits E, Chen Z, Maira SM, García-Echeverría C, Wong KK, Engelman JA.Proc Natl Acad Sci U S A. 2009 Nov 17;106(46):19503-8. doi: 10.1073/pnas.0905056106. Epub 2009 Oct 22.PMID: 19850869